Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.0386 EUR
−36.16 M EUR
56.24 M EUR
343.99 M
About Ocumension Therapeutics
Sector
CEO
Ye Liu
Website
Headquarters
Suzhou
Founded
2017
Identifiers
2
ISIN:KYG674111011
Ocumension Therapeutics engages in the identification, development, and commercialization of ophthalmic therapies. It provides pharmaceutical solutions to address significant unmet ophthalmic medical needs. The company was founded in 2017 and is headquartered in Suzhou, China.
Related stocks
Displays a symbol's price movements over previous years to identify recurring trends.
513120
GF CSI Hong Kong Brand Name Drug Exchange Traded Fund UnitsWeight
0.58%
Market value
11.09 M
USD
159567
Yinhua China Sec Hong Kong Stock Connect Innovative Drug EtfWeight
0.44%
Market value
1.83 M
USD
513780
INVESCO Great Wall CSI Hong Kong Connect Innovative Drug Exchange Traded Fund UnitsWeight
0.80%
Market value
1.24 M
USD
520700
Wanjia CSI Hong Kong Connect Innovative Drug Exchange Traded Fund UnitsWeight
0.77%
Market value
552.04 K
USD
520500
Huatai-PB Hang Seng Innovative Medicine Exchange Traded Fund UnitsWeight
0.54%
Market value
509.63 K
USD
Explore more ETFs
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange Ocumension Therapeutics stocks are traded under the ticker 5DG.
Yes, you can track Ocumension Therapeutics financials in yearly and quarterly reports right on TradingView.
Ocumension Therapeutics is going to release the next earnings report on Mar 20, 2026. Keep track of upcoming events with our Earnings Calendar.
5DG earnings for the last half-year are −0.02 EUR per share, whereas the estimation was −0.01 EUR, resulting in a −41.67% surprise. The estimated earnings for the next half-year are 0.00 EUR per share. See more details about Ocumension Therapeutics earnings.
Ocumension Therapeutics revenue for the last half-year amounts to 34.83 M EUR, despite the estimated figure of 37.63 M EUR. In the next half-year revenue is expected to reach 61.80 M EUR.
5DG net income for the last half-year is −15.37 M EUR, while the previous report showed −15.77 M EUR of net income which accounts for 2.55% change. Track more Ocumension Therapeutics financial stats to get the full picture.
No, 5DG doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 11, 2025, the company has 489 employees. See our rating of the largest employees — is Ocumension Therapeutics on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Ocumension Therapeutics EBITDA is −18.31 M EUR, and current EBITDA margin is −52.20%. See more stats in Ocumension Therapeutics financial statements.
Like other stocks, 5DG shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Ocumension Therapeutics stock right from TradingView charts — choose your broker and connect to your account.